The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neurotrophic Factor Therapies for Parkinson's Disease, 2010Intermittent Bilateral Intraputamenal Treatment with GDNF
Objective/Rationale:
Glial cell-derived neurotrophic factor (GDNF) has been shown in various pre-clinical models of Parkinson's disease (PD) to restore damaged nerve cells, including dopamine... -
Therapeutics Development Initiative, 2010Flibanserin in Levodopa-induced Dyskinesia: MPTP-lesioned Pre-clinical Model
Objective/Rationale:
Different mechanisms of action are considered relevant for provoking the involuntary abnormal jerking and hyperextensive or writhing-like twisting and turning movements called... -
Therapeutics Development Initiative, 2010Investigation of PDE10a Inhibitors for Parkinsons Disease.PI is Bart Ellenbroek
Objective/Rationale:
Phosphodiesterase 10A (PDE10A) is an intracellular protein that is located almost exclusively within the basal ganglia. It plays an important role in information transfer within... -
Therapeutics Development Initiative, 2010Targeting alpha-synuclein-lipid interactions in preclinical Parkinson's disease models
Objective/Rationale:
Parkinson’s disease is caused by loss of dopaminergic neurons in significant part secondary to accumulation/aggregation of a protein called a-synuclein. New information has shown... -
Therapeutics Development Initiative, 2010Assessment of the Neurorestorative Potential of Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Pre-clinical Model of PD
Objective/Rationale:
Parkinson’s is a neurodegenerative disease of the part of the brain that controls motor function. Brain-derived neurotrophic factors promote survival of dopaminergic neurons... -
Therapeutics Development Initiative, 2010Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Promising Outcomes of Original Grant:
The major objectives of the original grant were to improve upon the μ receptor (MOR) selectivity of ADC5510 and to find compounds that had superior pharmacokinetic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.